Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Use of the cholesterol 24-hydroxylase inhibitor soticlestat as adjunctive therapy in patients with Lennox–Gastaut syndrome (LGS) falls short of reducing the frequency of major motor drop (MMD) seizures, according to the results of the phase III SKYWAY trial.

Adjunctive soticlestat minimally beneficial in Lennox–Gastaut syndrome

Real-world evidence positions nirsevimab ahead in infant RSV prevention

Respiratory syncytial virus (RSV) remains a leading cause of hospitalisation and severe lower respiratory tract infection (LRTI) in infants worldwide. [Lancet 2022;399:2047-2064; Lancet 2017;390:946-958] In recent years, two immunoprophylactic strategies have become available to protect infants, namely maternal immunisation with the RSV prefusion F (RSVpreF) vaccine and passive immunisation of infants with the long-acting monoclonal antibody nirsevimab.

Real-world evidence positions nirsevimab ahead in infant RSV prevention

Can prednisolone be used in place of hydrocortisone in adrenal insufficiency?

The use of once-daily, low-dose prednisolone for glucocorticoid replacement in adrenal insufficiency yields substantial improvements in bone turnover and cardiometabolic health markers compared with multiple-dose hydrocortisone, according to the results of a crossover randomized clinical trial.

Can prednisolone be used in place of hydrocortisone in adrenal insufficiency?

ACS patients with SLE require greater healthcare use

Systemic lupus erythematosus (SLE) patients with acute coronary syndrome (ACS) need a longer hospital stay and accrue higher charges, resulting in higher healthcare utilization, reports a study.

ACS patients with SLE require greater healthcare use

More aggressive LDL-C reduction improves cardiac outcomes in ASCVD patients

An intensive targeting of low-density lipoprotein cholesterol (LDL-C) level (<55 mg/dL) reduces the risk of cardiovascular events at 3 years in patients with atherosclerotic cardiovascular disease (ASCVD) when compared with conventional targeting (<70 mg/dL), results of the Ez-PAVE trial have shown.

More aggressive LDL-C reduction improves cardiac outcomes in ASCVD patients

13 Apr 2026

Early onset, recurrent illness tied to DADA2 disease damage

In patients with deficiency of adenosine deaminase 2 (DADA2) vasculitis, early age of onset and periodic illness are associated with disease-related damage, but prompt initiation of a tumour necrosis factor inhibitor (TNFi) may prevent complications and severe progression, suggests a study.

Early onset, recurrent illness tied to DADA2 disease damage

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

Biomarker testing where appropriate and novel tailored combination therapies targeting multiple pathways simultaneously may address the high unmet need and optimize treatment outcomes in hormone receptor–positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (mBC) patients who develop resistance or have disease recurrence while on endocrine-based therapy (ET), said Professor Sherko Kümmel of the Interdisciplinary Breast Unit Clinics, Essen-Mitte, Germany, who spoke at the 14^th Asia-Pacific Breast Cancer Summit (APBCS 2026).

Novel combination therapies show potential in management of endocrine resistance in HR+/HER2- mBC

LEVI-04 improves knee osteoarthritis outcomes

Treatment with LEVI-04—a p75 neurotrophin receptor (p75NTR) fusion protein that inhibits neurotrophin-3—helps improve pain and function in patients with knee osteoarthritis, as shown in a phase II trial.

LEVI-04 improves knee osteoarthritis outcomes

Semaglutide & liraglutide lower risk of worsening mental illness

Use of semaglutide and, to a lesser extent, liraglutide is associated with significantly lower risk of worsening mental illness in patients with depression or anxiety vs non-use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a national cohort study has found.

Semaglutide & liraglutide lower risk of worsening mental illness

13 Apr 2026

Perioperative EV plus pembro tied to better outcomes in patients with MIBC

Perioperative treatment with enfortumab vedotin and pembrolizumab (EV plus pembro) significantly improves event-free survival (EFS), overall survival (OS), and pathological complete response (pCR) rates in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, according to the KEYNOTE-905 trial presented at EAU26.

Perioperative EV plus pembro tied to better outcomes in patients with MIBC